Outcomes in patients with anthracycline ‐induced cardiomyopathy undergoing left ventricular assist devices implantation

ConclusionsAfter receiving a CF-LVAD, survival in patients with anthracycline-induced cardiomyopathy is similar to those with ICM or IDM. Further research into differential secondary endpoints-related disparities is warranted.

Source: ESC Heart Failure - May 13, 2021 Category: Cardiology Authors: Avirup Guha, Cesar Caraballo, Prantesh Jain, P. Elliott Miller, Jocelyn Owusu ‐Guha, Katherine A.A. Clark, Eric J. Velazquez, Tariq Ahmad, Lauren A. Baldassarre, Daniel Addison, Neal L. Weintraub, Nihar R. Desai Tags: Original Research Article Source Type: research